ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 17% YoY consolidated growth. |
|---|---|
| Margins | EBITDA margin up from 8.5% to 12.5%. |
| Order book | Healthy order inflows and RFP conversion driving CDMO growth. |
| Demand visibility | Strong RFP activity in CDMO; power brands growing at mid-teens. |
| Management confidence | High; guided for sustained momentum and margin expansion. |
Growth
Revenue grew 17% YoY to ₹2,270Cr; EBITDA margin expanded 400bps to 12.5%.
Outlook
Expects sustained revenue growth and EBITDA expansion through FY27; Kenalog supplies to start Q2FY27.
Risks
Prolonged customer decision-making timelines in CDMO; raw material inflation and supply-chain headwinds mentioned.
Investor Presentation filed with NSE, NSE: PPLPHARMA. Summary written with AI assistance from the document.
Piramal Pharma Ltd: key numbers
- Share price
- ₹248.95
- Market cap
- ₹33,144 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -158.7×Sector 43.8×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Capital Structure Change
HDFC Mutual Fund schemes reduced their Piramal Pharma stake by 2.027% via open market sale on 28 October 2026. Holding fell from 7.015% to 4.988%.
Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.